D S Lim1, R Roberts, A J Marian. 1. Section of Cardiology, Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA.
Abstract
OBJECTIVES: The goal of this study was to identify genes upregulated in the heart in human patients with hypertrophic cardiomyopathy (HCM). BACKGROUND: Hypertrophic cardiomyopathy is a genetic disease caused by mutations in contractile sarcomeric proteins. The molecular basis of diverse clinical and pathologic phenotypes in HCM remains unknown. METHODS: We performed polymerase chain reaction-select complementary DNA subtraction between normal hearts and hearts with HCM and screened subtracted libraries by Southern blotting. We sequenced the differentially expressed clones and performed Northern blotting to detect increased expression levels. RESULTS: We screened 288 independent clones, and 76 clones had less than twofold increase in the signal intensity and were considered upregulated. Sequence analysis identified 36 genes including those encoding the markers of pressure overload-induced ("secondary") cardiac hypertrophy, cytoskeletal proteins, protein synthesis, redox system, ion channels and those with unknown function. Northern blotting confirmed increased expression of skeletal muscle alpha-actin (ACTA1), myosin light chain 2a (MLC2a), GTP-binding protein Gs-alpha subunit (GNAS1), NADH ubiquinone oxidoreductase (NDUFB10), voltage-dependent anion channel 1 (VDAC1), four-and-a-half LIM domain protein 1 (FHL1) (also known as SLIM1), sarcosin (SARCOSIN) and heat shock 70kD protein 8 (HSPA8) by less than twofold. Expression levels of ACTA1, MLC2a and GNAS1 were increased in six additional and FHL1 in four additional hearts with HCM. CONCLUSIONS: A diverse array of genes is upregulated in the heart in human patients with HCM, which could account for the diversity of clinical and pathologic phenotypes. Markers of secondary hypertrophy are also upregulated, suggesting commonality of pathways involved in HCM and the acquired forms of cardiac hypertrophy. Elucidation of the role of differentially expressed genes in HCM could provide for new therapeutic targets.
OBJECTIVES: The goal of this study was to identify genes upregulated in the heart in humanpatients with hypertrophic cardiomyopathy (HCM). BACKGROUND:Hypertrophic cardiomyopathy is a genetic disease caused by mutations in contractile sarcomeric proteins. The molecular basis of diverse clinical and pathologic phenotypes in HCM remains unknown. METHODS: We performed polymerase chain reaction-select complementary DNA subtraction between normal hearts and hearts with HCM and screened subtracted libraries by Southern blotting. We sequenced the differentially expressed clones and performed Northern blotting to detect increased expression levels. RESULTS: We screened 288 independent clones, and 76 clones had less than twofold increase in the signal intensity and were considered upregulated. Sequence analysis identified 36 genes including those encoding the markers of pressure overload-induced ("secondary") cardiac hypertrophy, cytoskeletal proteins, protein synthesis, redox system, ion channels and those with unknown function. Northern blotting confirmed increased expression of skeletal muscle alpha-actin (ACTA1), myosin light chain 2a (MLC2a), GTP-binding protein Gs-alpha subunit (GNAS1), NADH ubiquinone oxidoreductase (NDUFB10), voltage-dependent anion channel 1 (VDAC1), four-and-a-half LIM domain protein 1 (FHL1) (also known as SLIM1), sarcosin (SARCOSIN) and heat shock 70kD protein 8 (HSPA8) by less than twofold. Expression levels of ACTA1, MLC2a and GNAS1 were increased in six additional and FHL1 in four additional hearts with HCM. CONCLUSIONS: A diverse array of genes is upregulated in the heart in humanpatients with HCM, which could account for the diversity of clinical and pathologic phenotypes. Markers of secondary hypertrophy are also upregulated, suggesting commonality of pathways involved in HCM and the acquired forms of cardiac hypertrophy. Elucidation of the role of differentially expressed genes in HCM could provide for new therapeutic targets.
Authors: J Zuber; O I Tchernitsa; B Hinzmann; A C Schmitz; M Grips; M Hellriegel; C Sers; A Rosenthal; R Schäfer Journal: Nat Genet Date: 2000-02 Impact factor: 38.330
Authors: M Mao; G Fu; J S Wu; Q H Zhang; J Zhou; L X Kan; Q H Huang; K L He; B W Gu; Z G Han; Y Shen; J Gu; Y P Yu; S H Xu; Y X Wang; S J Chen; Z Chen Journal: Proc Natl Acad Sci U S A Date: 1998-07-07 Impact factor: 11.205
Authors: L Diatchenko; Y F Lau; A P Campbell; A Chenchik; F Moqadam; B Huang; S Lukyanov; K Lukyanov; N Gurskaya; E D Sverdlov; P D Siebert Journal: Proc Natl Acad Sci U S A Date: 1996-06-11 Impact factor: 11.205
Authors: Anna Raskin; Stephan Lange; Katherine Banares; Robert C Lyon; Anke Zieseniss; Leonard K Lee; Katrina G Yamazaki; Henk L Granzier; Carol C Gregorio; Andrew D McCulloch; Jeffrey H Omens; Farah Sheikh Journal: J Biol Chem Date: 2012-07-09 Impact factor: 5.157
Authors: Tong Tang; N Chin Lai; H Kirk Hammond; David M Roth; Yuan Yang; Tracy Guo; Mei Hua Gao Journal: J Am Coll Cardiol Date: 2010-04-06 Impact factor: 24.094
Authors: Danos C Christodoulou; Hiroko Wakimoto; Kenji Onoue; Seda Eminaga; Joshua M Gorham; Steve R DePalma; Daniel S Herman; Polakit Teekakirikul; David A Conner; David M McKean; Andrea A Domenighetti; Anton Aboukhalil; Stephen Chang; Gyan Srivastava; Barbara McDonough; Philip L De Jager; Ju Chen; Martha L Bulyk; Jochen D Muehlschlegel; Christine E Seidman; J G Seidman Journal: J Clin Invest Date: 2014-02-10 Impact factor: 14.808
Authors: Heather R Tiffin; Zandra A Jenkins; Mary J Gray; Sophia R Cameron-Christie; Jennifer Eaton; Salim Aftimos; David Markie; Stephen P Robertson Journal: Neurogenetics Date: 2013-03-02 Impact factor: 2.660